QualityStocksNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Reports Extended Phase 2a Results for SGX302 Gel in Mild-to-Moderate Psoriasis
Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on treatments for rare diseases with unmet medical need, reported extended results from its ongoing Phase 2a trial evaluating SGX302 (synthetic hypericin) for mild-to-moderate psoriasis, including outcomes from an additional cohort treated with an optimized topical gel formulation. The gel was well tolerated with no drug-related adverse events and demonstrated improvements across multiple clinical and quality-of-life measures, including Investigator Global Assessment and Psoriasis Area and Severity Index scores, with results comparable to or exceeding those observed with the prior ointment formulation, supporting continued development of SGX302 as a potential non-carcinogenic, non-mutagenic therapeutic…